Michael Hayden, PhD, Chief Executive Officer of Prilenia Therapeutics, talks about the PROOF-HD trial currently underway to treat Huntington disease.
Huntington disease is an inherited, neurodegenerative disorder that usually begins to be symptomatic starting at around 40 years of age. Persons with Huntington disease suffer from a progressive movement disorder, cognitive decline, psychiatric disturbances, and behavioral symptoms. All symptoms progress which eventually leads to immobility, dementia and premature death.
PROOF-HD is a pivotal, phase 3 clinical trial assessing the efficacy and safety of pridopidine in patients with Huntington disease. Dr. Hayden noted that the primary endpoint of the trial is total functional capacity (TFC). The TFC scale assesses how people with HD manage their work, finances, daily living, domestic chores, and their care.
The clinical trial is being conducted at numerous sites in North America and Europe. For more information about the trial, visit clinicaltrials.gov/ct2/show/NCT04556656
To stay informed about the latest developments in Huntington disease, sign up for our newsletter at checkrare.com/sign-up-for-our-newsletter/
